The recent article by Arber et al (1) detailing the 2016 revision of the World Health Organization (WHO) classification of myeloid malignancies and AML was timely and germane. Regarding myelodysplastic syndromes (MDS), the authors indicate diagnostic criteria, which include levels of dysplasia and cytopenias. They further indicated that ethnic variation should be taken into consideration in patients with borderline low neutrophil counts and that a diagnosis of MDS may still be made in 'rare cases with milder levels of cytopenia' when definitive morphologic and/or cytogenetic features are present (1, 2) . The necessity of clarifying these criteria has major relevance, particularly with the advent of recently described group of indolent hematopoietic disorders which may represent precursor states of MDS such as idiopathic cytopenia of unknown significance (ICUS) (3) (4) (5) , Idiopathic dysplasia of unknown significance (IDUS) (5, 6) , clonal hematopoiesis of unknown potential (CHIP) (7), and clonal cytopenia of unknown significance (CCUS) (4, 8, 9) 
These entities have been reviewed in the current NCCN MDS Practice Guidelines 1.2017 (10) .
However, although the WHO perspective indicates that 'cytopenia is a sine qua non for any MDS diagnosis' (1), the recommended threshold levels of cytopenias they propose for this purpose are those previously reported in the International Prognostic Scoring System (IPSS) risk stratification categorization, that were used for prognostic but not diagnostic purposes [hemoglobin (Hb) 10g/dL, absolute neutrophil count (ANC) 1.8x10 9 /L, platelets 100x10 9 /L] (11). As shown in Table 1 , providing data from the International Working Group for Prognosis in MDS (IWG-PM) database that was used to generate the Revised-IPSS (IPSS-R) (12) , were these levels of cytopenias to be used to diagnose MDS, 18% of MDS patients and 23% of those with <5% marrow blasts, would lack any cytopenia and thus would not be classifiable as MDS. Using standard laboratory values for cytopenias [Hb <13g/dL (males), <12g/dL (females), ANC <1.8x10 9 /L, platelets <150x10 9 /L], the data demonstrated that only 1.8% patients evaluated in that study of 7012 MDS subjects would lack a cytopenia (1.3% patients when non-proliferative CMML patients were excluded). Of note, and relevant predominantly for patients with low marrow blast counts in the IWG-PM cohort, the patient's blood counts also needed to demonstrate ≥ 2 months of stable disease as a potential means of excluding other causes for the cytopenias.
Regarding our main point, it is of relevance that the MDS database (n=816) used to generate the IPSS (11, Table 1 ) similarly demonstrated that 19% of these patients lacked a cytopenia if defined by the prognostic level cutpoints used by the WHO and also incorrectly would not have been considered to have MDS. Similar findings were found in an independent study using these cytopenic cutpoints (13) . Prior investigations have demonstrated ethnic-, age-and altituderelated differences in normal hemoglobin levels (14, 15) , ethnic-, age-and sexrelated differences in platelet levels (16, 17) , and ethnic-and sex-related differences in platelet and white counts (18) . Thus, being cognizant of these conditional blood count variations, we recommend that standard hematologic values be used to define cytopenias in MDS and believe a modification of the WHO definition of cytopenias as one of the criteria (in addition to definitive morphologic and/or cytogenetic findings) to diagnose MDS would be valuable and most accurate. 
